SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as community members rally around anticipation of a major upcoming partnership announcement, widely speculated to involve Ripple or XRP, alongside excitement over its new global stablecoin payroll integration with Stellar. While some investors focus on long-term utility and potential listings on major exchanges, community discourse remains polarized between optimistic holders eyeing generational wealth and skeptics dismissing recent price action as a pump-and-dump cycle.

Maul Coin

Maul Coin is trending as the community actively coordinates to push the token's visibility on social platforms and trading sites, fueled by an active developer and hopes of reaching higher market caps. While enthusiasts celebrate its organic growth and community-driven approach, skeptics remain vocal about concerns regarding potential volatility, lack of a chart, and typical risks associated with low-cap crypto projects.

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

VEIL is trending as community members rally behind its privacy-focused technology on the Base network, often citing support from Coinbase Ventures as a key catalyst. Enthusiasts are actively discussing the project's long-term potential for adoption and its mining and staking features, viewing it as a essential tool for digital sovereignty.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as investors highlight its ultra-low circulating supply and small market capitalization as key drivers for significant growth potential. The community is actively discussing the token's upside, with many calling for increased volume and exchange listings to catalyze a major breakout.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is capturing significant trader attention as a high-performance Layer 1 blockchain, with the community actively debating its potential to rival existing networks through speed and parallel processing. While price action has seen volatility alongside broader crypto market trends, discussions are heavily focused on long-term accumulation, staking rewards, and anticipation of upcoming ecosystem developments.

Monero

Monero is seeing heightened activity as community members debate its status as the leading privacy-focused asset amid ongoing regulatory scrutiny and discussions regarding its long-term viability as a secure alternative to more transparent cryptocurrencies. Enthusiasts are actively comparing its unique privacy features to other assets, frequently highlighting its role in personal financial sovereignty while tracking its performance through market volatility.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is currently facing significant downward pressure and investor frustration, with the community actively debating whether the stock is a long-term 'holy grail' opportunity or a failing venture as it sits at a critical technical support level. Investors remain highly focused on upcoming manufacturing milestones and the potential for a short squeeze, while sentiment is polarized between those accumulating shares for a multi-year horizon and others disillusioned by the lack of immediate commercial catalysts.

"What's Updog?" is a Community Led token.

UpDog

The UpDog community is rallying around the project's longevity and humorous branding, actively promoting the token's presence across major platforms and cross-promoting with other popular assets. Enthusiasts are focused on organic growth and widespread adoption, frequently engaging with the community through social memes and dedicated poker events.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is currently experiencing significant market movement and high volume driven by intense community speculation regarding a potential buyout or M&A activity. The stock has seen unusual after-hours trading and sustained call option accumulation, leading investors to closely monitor for official announcements or catalyst-driven price volatility.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is experiencing heightened volatility and intense social media discussion as the community debates its valuation and high price-to-earnings ratio ahead of its earnings release. While some investors remain cautious about margin pressures and the macro environment, others are highlighting strong unit-level economics, rapid store expansion, and high customer loyalty as reasons to hold the stock through the uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Janux Therapeutics Secures $35M Milestone Payment From BMY Deal

JANX earns $35M milestone payment from Bristol Myers as TRACTr-based cancer candidate advances, signaling progress in its tumor-activated therapy platform.

OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study

Ocugen completes GARDian3 enrollment early as OCU410ST gene therapy targets Stargardt disease with no approved treatments. Data readouts are expected in Q3. 

Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus

KOD posts wider Q4 loss. However, its pipeline advances, with strong phase III data for Zenkuda driving accelerated regulatory plans.

AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD

Agios Pharmaceuticals jumps 14% as it moves toward accelerated FDA approval for mitapivat in sickle cell disease after key regulatory feedback.

AZN Posts Data From Hypophosphatasia Program on Efzimfotase Alfa

AstraZeneca reports phase III data showing efzimfotase alfa improves bone health in children with HPP, with mixed adult results and an overall favorable safety profile.

Can ANI (ANIP) Climb 43.86% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for ANI (ANIP) points to a 43.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

ANIP Stock Outlook: Cortrophin Growth vs. Retina Reset

ANI Pharmaceuticals' growth pivots to Cortrophin Gel as retina headwinds weigh on 2025, with 2026 recovery hopes hinging on specialty momentum and portfolio reset.

Is ANIP Undervalued? How to Read Its 9.3x Forward P/E

ANI Pharmaceuticals trades at just 9.3x forward earnings, far below peers - raising a key question: is this a bargain or a signal of execution risks ahead?

ANI Pharmaceuticals 2026 Watchlist: Gout Sales Force and Rare Disease

ANIP eyes 2026 pivot as Rare Disease targets 60% of sales, with Cortrophin growth, gout sales force expansion, and retina rebound shaping momentum.

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

ANI Pharmaceuticals Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$74.21
Prev Close	$75.96
Open	$75.10
Dividend Yield	0.00%
50-Day Moving Average	$76.94
Beta	0.64
Avg. Volume	373,026.32
PE Ratio	22.14

52-Week High	$99.50
52-Week Low	$56.71
Market Capitalization	$1.66B
EPS (Annual)	$3.32
Price to Book	3.09
Revenue Per Employee	$910,686.60

ANIP
ANI Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANIP News

ANIPANI Pharmaceuticals Inc